Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome

• DOI: 10.1080/13696998.2022.2027706
• Publication Date: 2022-01-12T20:28:47Z
• Authors: Adrian R. Levy; Peter Chen; Karissa Johnston; Yan Wang; Evan Popoff; Ioannis Tomazos
• Keywords: Eculizumab

This study compared the aggregate duration of treatment administration approved eculizumab and ravulizumab regimens resultant productivity implications for patients with atypical hemolytic uremic syndrome (aHUS) their caregivers.The (which includes waiting time medication preparation infusion, recovery, travel to from clinic) was determined a hypothetical population aHUS treated (10 mg/mL) or 100 mg/mL), in clinic at home, 1 year, Germany, Italy, UK, US. The data US used extend previously published cost-minimization model (CMM) estimate annual lost associated compare overall costs adult pediatric US.The 10 mg/mL reduced by 44-52% 69-74%, respectively, mg/mL, across all four countries. Using CMM, patient due were 56-60% 73-76% discounted (direct owing treatment) vs patients.This based on patients, assumptions made regarding caregiver involvement, characteristics, patterns.Compared eculizumab, reduces treatment. reduction is greater formulation, shorter infusion times this more concentrated formulation.PLAIN LANGUAGE SUMMARY[Figure: see text][Figure: text].